David Q. Anderson

David Q. Anderson is a Partner at Ampersand Capital Partners, a Boston-based private equity firm focused on the heathcare sector.  Prior to joining Ampersand in 2010 David spent six years with Covington Associates, a specialty investment bank executing M&A transactions in middle-market healthcare. Prior to Covington, he spent five years as a consultant for Boston Healthcare Associates specializing in strategic planning for emerging biopharmaceutical, medical device and diagnostics companies. In addition to Brammer David sits on the board of BioClinica, IFP, and Elite One Source. David holds a B.Sc. in Immunology from the University of Aberdeen, Scotland, a Ph.D. in Tumor Immunobiology from the University of Sheffield, England and an M.B.A. from Babson College, Wellesley, MA. 

Mark R. Bamforth

President and CEO, Founder

In 2015 Mark founded Brammer Biopharmaceuticals, a cell and gene therapy CMO, subsequently merged in March 2016 with Florida Biologix to create Brammer Bio.  Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian based biopharmaceuticals which was sold to DPx Holdings B.V. (Patheon) in September 2014.  Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp.  His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. Mark began his career as a petroleum engineer, exploring for North Sea oil, then as a chemical engineer in the whisky industry. He serves on the MassBio Board and is a founding trustee of the Saltire Foundation.  He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Herb Hooper

Herb Hooper is a Managing Partner at Ampersand Capital, a healthcare-focused private equity firm in the Boston area where he has been a partner since 2002.   Prior to Ampersand, Herb was a co-founder and Chief Scientific Officer of Aclara Biosciences, a pioneering lab-on-a chip company that completed an IPO in 2000.  Herb holds a PhD in Chemical Engineering from the University of California, Berkeley, and a BS in Chemical Engineering from NC State University.  He has served as a Board member for over a dozen public and private life sciences companies.  Herb also serves on the Advisory Board for UC Berkeley’s College of Chemistry.  

Steve Jungles

Steve Jungles currently serves as a CMC consultant for early-stage orphan disease companies.  Before that, Mr. Jungles served as Senior Vice President Technical Operations at Ultragenyx Pharmaceutical from August 2011 until March 2015, as Vice President of Contract Manufacturing and Supply Chain at BioMarin Pharmaceutical from June 1999 until July 2011, and as Associate Director at Harvard Gene Therapy Initiative from June 1997 to June 1999.  Mr. Jungles received a B.S. in Biology from the University of Iowa.  He has extensive leadership and management experience and continues to be active in the life sciences industry. 

Steven H. Kasok

Chief Financial Officer (CFO), Founder

Together with Mark, Steve founded Brammer and Gallus.  As Chief Financial Officer he has direct responsibility for finance, human resources, information technology, and legal functions. Previously, Steven served as Vice President and Treasurer of Millipore Corporation; Chief Financial Officer of Cabot Supermetals, Treasurer and Business Development Officer at Haemonetics Corp. and a variety of roles within Converse Inc. and GE.  Steven earned a B.S. in Finance from Clarkson University and a M.B.A. from Harvard Business School. 

Richard O. Snyder, Ph.D

Chief Scientific Officer, Founder  

Dr. Snyder was the founder of Florida Biologix, which was spun out of the University of Florida in 2015 and merged to create Brammer Bio.  Dr. Snyder has been investigating virus biology, vector development, cGMP manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 30 years, and was a member of teams who developed novel viral vector-based human gene therapies.  Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications.  Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis.  Dr. Snyder has authored over 60 publications and 8 US patents. 


Patrick D. Walsh

Patrick D. Walsh is an experienced board of director having served as Chairman, Non-Executive Chairman and a company Director in numerous healthcare organizations as well as an Executive Advisor to private equity and venture capital firms.  Patrick is currently CEO of Avista Pharma Solutions, an Ampersand portfolio company providing contract services to the pharmaceutical industry. He has extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations. Prior to Avista Pharma, Patrick was CEO of AAIPharma Services, where he led the successful growth strategy culminating in the sale of the company for a 4.6 times return on invested capital.  Prior executive roles include several CEO roles in life science companies and he also served as President & COO of Gensia-Sicor.